Immunotherapy plus chemo then chemoradiation for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests whether adding tislelizumab (an immunotherapy drug) to chemotherapy before a combined course of chemotherapy and radiation can better treat locally advanced, non-surgable esophageal squamous cell cancer. It’s for adults who cannot have surgery and may help shrink the cancer and improve control of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed localized esophageal squamous cell cancer that cannot be removed with surgery (or you refuse surgery), with stage II to IVA.
- You’re age 18 to 70, and you can’t have had other esophageal cancer treatments like prior PD-1/PD-L1 immunotherapy, radiation, targeted therapy, ablation, or other anti-cancer drugs for this cancer.
- You can do study tests and treatments with an overall health score (ECOG) of 0 to 1.
- Your cancer must have measurable or non-measurable target spots that doctors can track by scan (RECIST 1.1).
- Your blood and organ tests must be strong enough: enough white cells, hemoglobin, and platelets; kidneys and liver function within allowed limits.
- You need enough expected life time (more than 6 months) and must agree to approved birth control during treatment and for at least 3 months after the last dose (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of short-course radiation, an immunotherapy drug called tislelizumab, and chemotherapy before surgery for esophageal cancer that has spread to nearby lymph nodes but hasn't spread to distant organs. The goal is to shrink the tumor before surgery and improve outcomes.
This trial tests a combination of an immunotherapy drug (tislelizumab) with standard chemotherapy given before and after surgery for esophageal cancer. It aims to see if this approach can improve treatment outcomes for patients with a certain stage of the disease.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests if adding the immunotherapy drug tislelizumab to standard chemotherapy before surgery or radiation can improve outcomes for people with resectable esophageal squamous cell carcinoma. It is designed for patients whose cancer is in the chest and has not spread to distant organs.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
Hear when a new Immunotherapy Esophagus Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.